Numab
David Hong, M.D., is a Professor of Medicine and the Associate Vice President of Clinical Research at MD Anderson Cancer Center. Throughout his career, Dr. Hong has developed an interest in studying the efficacy of novel drug combinations in patients with solid tumors. Recently his research endeavors have focused on developing personalized therapies for patients, whose tumors bear specific genetic mutations/amplifications and combining targeted therapies with immunotherapies.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Numab
Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, they are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.